Company research
Lunai Bioworks Inc.
CIK 1527728Updated Nov 13, 2026
Securities
Historical securities (1)
LNAI · OTC · equity · closed Oct 30, 2026Name history
RENOVARO INC. · through Aug 26, 2025RENOVARO BIOSCIENCES INC. · through Feb 7, 2024Enochian Biosciences Inc · through Aug 1, 2023DanDrit Biotech USA, Inc. · through Feb 23, 2018Putnam Hills Corp. · through Feb 11, 2014
LNAI price & chart
Historical security
This listing closed Oct 30, 2026. Live provider charts are shown only for current listings.
About the company
Lunai Bioworks (NASDAQ: LNAI) is an AI-driven life sciences company advancing drug discovery through its integrated platform. The Company combines clinical data, machine learning, and in vivo validation to identify disease biology and develop precision therapeutics. Lunai is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates.
In the news
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit ↗
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research ↗
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common Stock ↗
Recent filings
15-12G filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
25 filing
EFFECT filing
S-8 POS filing
Show 5 more recent filings
POS AM filing
S-8 POS filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other Events
Items 3.01, 5.02, 7.01, 8.01, 9.01
10-K filing
Other Events
Items 8.01, 9.01
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 9,860,540Source | 117,726,120Source | 178,089,340Source | 6,666,446Source | 111,340,272Source | 58,018,120Source | 6,960,663Source | 121,832,637Source | 9,941,788Source | 8,230,840Source | 163,129,450Source | 58,300,796Source |
| Property, Plant and Equipment, NetUSD | 12,956Source | 393,119Source | 488,915Source | 13,253Source | 422,032Source | 496,896Source | 12,465Source | 452,212Source | 12,015Source | 367,843Source | 482,121Source | 508,989Source |
| GoodwillUSD | 5,963,000Source | 112,642,272Source | 164,186,852Source | 5,963,000Source | 107,999,273Source | 11,640,000Source | 5,963,000Source | 118,171,345Source | 5,963,000Source | 5,963,000Source | 159,330,161Source | 11,640,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,155,272Source | 923,002Source | 312,697Source | 491,645Source | 311,764Source | 243,980Source | 624,808Source | 220,571Source | 1,713,653Source | 92,700Source | 220,467Source | 1,874,480Source |
| Assets, CurrentUSD | 3,732,650Source | 3,668,054Source | 1,219,915Source | 514,489Source | 1,708,261Source | 2,403,150Source | 800,360Source | 1,948,159Source | 2,036,393Source | 1,046,632Source | 1,997,643Source | 2,565,405Source |
| Operating Lease, Right-of-Use AssetUSD | — | 992,357Source | 1,385,619Source | — | 1,180,799Source | 812,691Source | — | 1,150,474Source | — | 687,371Source | 1,269,633Source | 913,985Source |
| Other Assets, NoncurrentUSD | 6,114,934Source | 113,664,947Source | 176,380,510Source | 6,138,704Source | 109,209,979Source | 55,118,074Source | 6,147,838Source | 119,432,266Source | 7,893,380Source | 6,816,365Source | 160,649,686Source | 55,226,402Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 19,413,968Source | 29,339,269Source | 43,683,784Source | 20,215,234Source | 29,280,954Source | 14,422,584Source | 20,001,437Source | 23,745,639Source | 18,966,734Source | 29,580,681Source | 31,152,306Source | 11,798,685Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | — | — | 56Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 3,577Source | 16,241Source | 15,093Source | 2,419Source | 16,216Source | 6,724Source | 2,318Source | 16,106Source | 462Source | 17,741Source | 15,847Source | 6,371Source |
| Additional Paid in CapitalUSD | 502,613,040Source | 471,325,333Source | 450,079,965Source | 496,030,769Source | 469,810,215Source | 301,349,389Source | 494,728,618Source | 468,440,794Source | 505,155,698Source | 478,280,146Source | 464,587,224Source | 290,554,875Source |
| Retained Earnings (Accumulated Deficit)USD | -512,014,347Source | -383,730,334Source | -316,723,472Source | -509,442,953Source | -383,919,510Source | -257,733,402Source | -507,643,549Source | -376,667,117Source | -514,025,049Source | -510,462,570Source | -332,455,081Source | -244,029,253Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -155,698Source | 775,611Source | 1,033,970Source | -139,023Source | -3,847,603Source | -27,231Source | -128,161Source | 6,297,215Source | -156,057Source | 10,814,842Source | -170,846Source | -29,882Source |
| Stockholders' Equity Attributable to ParentUSD | -9,553,428Source | 88,386,827Source | 134,405,556Source | -13,548,788Source | 82,059,316Source | 43,595,536Source | -13,040,774Source | 98,086,998Source | -9,024,946Source | -21,349,841Source | 131,977,144Source | 46,502,111Source |
| Liabilities and EquityUSD | 9,860,540Source | 117,726,120Source | 178,089,340Source | 6,666,446Source | 111,340,272Source | 58,018,120Source | 6,960,663Source | 121,832,637Source | 9,941,788Source | 8,230,840Source | 163,129,450Source | 58,300,796Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 19,282,652Source | 28,841,640Source | 20,874,013Source | 20,001,577Source | 28,606,754Source | 13,758,366Source | 19,722,474Source | 23,035,379Source | 18,910,486Source | 29,156,134Source | 30,309,917Source | 11,023,098Source |
| Operating Lease, Liability, CurrentUSD | 288,390Source | 547,683Source | 483,226Source | 274,983Source | 562,287Source | 218,085Source | 277,775Source | 504,254Source | 293,787Source | 313,047Source | 493,553Source | 193,422Source |
| Operating Lease, Liability, NoncurrentUSD | 131,316Source | 497,629Source | 970,353Source | 213,657Source | 674,200Source | 664,218Source | 278,963Source | 710,260Source | 56,248Source | 424,547Source | 842,389Source | 775,587Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | 152,019Source | 271,643Source | 231,381Source | 184,733Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,912,750Source | 5,715,737Source | 3,754,976Source | 4,927,474Source | 5,512,004Source | 783,601Source | 4,868,686Source | 5,359,454Source | 5,019,389Source | 5,843,069Source | 5,311,324Source | 723,173Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | 91,387Source | — | — | — | — | — | 1,526,990Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | —Source | — | — | — | — | — | — | — | — | — | — |
| Prepaid Expense and Other Assets, Current | — | —Source | — | — | —Source | — | — | —Source | — | — | — | — |
| Accounts Payable, Current | — | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 189,176Source | -1,799,404Source | -7,252,394Source | 2,819,021Source | -44,212,036Source | -3,562,479Source | -178,007,489Source | -88,425,828Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 11,001Source | 31,975Source | 11,332Source | 32,109Source | 41,522Source | 32,385Source | 93,522Source | 129,095Source | 121,859Source | 113,496Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 168,993Source | 1,499,199Source | 128,819Source | 558,631Source | 181,312Source | 357,648Source | 630,389Source | 3,313,291Source | 4,673,129Source | 3,535,051Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 532,206Source | 1,953,539Source | 1,131,424Source | 3,106,181Source | 4,057,282Source | 3,894,955Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,349,110Source | -2,016,328Source | -5,288,197Source | -7,874,647Source | -10,971,430Source | -11,774,549Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 544,700Source | 0Source | 543,462Source | -500,000Source | -1,260,179Source | -29,774Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 1,238Source | — | 70,430Source | 29,774Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,343,357Source | 2,029,183Source | 6,391,458Source | 8,382,772Source | 10,517,455Source | 4,515,056Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 532,108Source | 104Source | 1,620,953Source | -127,767Source | -1,654,013Source | -7,297,662Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,155,272Source | 923,002Source | 491,645Source | 311,764Source | 624,808Source | 220,571Source | 1,713,653Source | 92,700Source | 220,467Source | 1,874,480Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 8,559Source | 0Source | 127,488Source | 24,555Source | 20,128Source | 352,334Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -6,839Source | -12,751Source | -25,770Source | -135,892Source | 60,141Source | -8,395Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 4,673,129Source | 3,535,051Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 63,279Source | 9,902Source | 8,296Source | 6,175Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 1,526,990Source |
| Debt and Equity Securities, Gain (Loss)USD | — | — | — | — | — | — | — | — | 0Source | 387,851Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 30,243Source | 119,193Source | 113,563Source | 107,321Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -16,675Source | 4,623,214Source | -10,862Source | -10,144,818Source | -10,943,003Source | 6,468,061Source | -10,970,899Source | 10,985,688Source | -140,964Source | — |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -1,019Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -1,086,116Source | 0Source | — | — | -6,329,592Source | 0Source | -7,415,708Source | 0Source | -1,303,578Source | -419,182Source |
| General and Administrative ExpenseUSD | — | — | 1,421,255Source | 4,224,590Source | 1,766,210Source | 4,353,123Source | 2,410,516Source | 5,301,251Source | 7,799,970Source | 17,880,050Source | 24,557,608Source | 15,318,198Source |
| GoodwillUSD | — | — | 5,963,000Source | 112,642,272Source | 5,963,000Source | 107,999,273Source | 5,963,000Source | 118,171,345Source | 5,963,000Source | 5,963,000Source | 159,330,161Source | 11,640,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | 0Source | — | 0Source | — | 47,614,729Source | 831,915Source | 170,419,429Source | 11,640,000Source | — |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | — | 0Source | 47,614,729Source | 0Source | 170,419,429Source | 11,640,000Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 831,915Source | — | 42,611,000Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | 0Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,406Source | 1,474Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 108,052Source | 188,685Source | 121,508Source | 98,891Source | 122,400Source | 250,080Source | 235,074Source | 725,684Source | 1,011,322Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,571,394Source | 189,176Source | -1,799,404Source | -7,252,394Source | 2,819,021Source | -44,212,036Source | -3,562,479Source | -178,007,489Source | -88,425,828Source | -39,684,056Source |
| Nonoperating Income (Expense)USD | — | — | -1,144,134Source | 4,351,688Source | 24,010Source | -2,706,078Source | 6,127,381Source | 9,126,518Source | 5,135,454Source | 10,958,513Source | -6,786,532Source | -1,127,165Source |
| Operating ExpensesUSD | — | — | 1,448,202Source | 4,162,492Source | 1,823,414Source | 4,546,316Source | 3,308,360Source | 53,338,554Source | 8,749,925Source | 188,966,002Source | 81,639,296Source | 38,556,891Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 383,549Source | 322,447Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 1,159,470Source | — | — |
| Amortization of Debt Issuance Costs and Discounts | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Equity Securities, FV-NI, Gain (Loss) | — | — | — | —Source | — | — | —Source | — | — | — | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Other Depreciation and Amortization | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 20,942Source | — | — | — | — | — | 51,992Source | — | — | — |
| Operating Income (Loss)USD | — | — | -1,477,260Source | -4,162,492Source | -1,823,414Source | -4,546,316Source | -3,308,360Source | -53,338,554Source | -8,697,933Source | -188,966,002Source | -81,639,296Source | -38,556,891Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -39,684,056Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,406Source | 1,474Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,571,394Source | 189,176Source | -1,799,404Source | -7,252,394Source | 2,819,021Source | -44,212,036Source | -3,562,479Source | -178,007,489Source | -88,425,828Source | -39,684,056Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.1Source | 0Source | -0.08Source | -0.45Source | 0.13Source | -2.76Source | -1.06Source | -1.08Source | -0.91Source | -0.71Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.1Source | 0Source | -0.08Source | -0.45Source | 0.13Source | -2.76Source | -1.06Source | -1.08Source | -0.91Source | -0.71Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 24,994,200Source | 16,233,457Source | 23,482,714Source | 16,182,521Source | 22,520,245Source | 15,999,337Source | 3,360,903Source | 165,061,967Source | 97,511,557Source | 56,265,362Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 24,994,200Source | 16,393,047Source | 23,482,714Source | 16,182,521Source | 22,520,245Source | 15,999,337Source | 3,360,903Source | 165,061,967Source | 97,511,557Source | 56,265,362Source |
| Interest Expense (non-operating)USD | — | — | 108,052Source | 188,685Source | 121,508Source | 98,891Source | 122,400Source | 250,080Source | 235,074Source | 725,684Source | 1,011,322Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 63,279Source | 9,902Source | 8,296Source | 6,175Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,406Source | 1,474Source | 0Source | — |
| Debt and Equity Securities, Gain (Loss)USD | — | — | — | — | — | — | — | — | 0Source | 387,851Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 41,522Source | 32,385Source | 93,522Source | 129,095Source | 121,859Source | 113,496Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -16,675Source | 4,623,214Source | -10,862Source | -10,144,818Source | -10,943,003Source | 6,468,061Source | -10,970,899Source | 10,985,688Source | -140,964Source | — |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -1,019Source |
| General and Administrative ExpenseUSD | — | — | 1,421,255Source | 4,224,590Source | 1,766,210Source | 4,353,123Source | 2,410,516Source | 5,301,251Source | 7,799,970Source | 17,880,050Source | 24,557,608Source | 15,318,198Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | — | 0Source | 47,614,729Source | 0Source | 170,419,429Source | 11,640,000Source | — |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | -3,562,479Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 580,344Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | -126,620Source |
| Nonoperating Income (Expense)USD | — | — | -1,144,134Source | 4,351,688Source | 24,010Source | -2,706,078Source | 6,127,381Source | 9,126,518Source | 5,135,454Source | 10,958,513Source | -6,786,532Source | -1,127,165Source |
| Operating ExpensesUSD | — | — | 1,448,202Source | 4,162,492Source | 1,823,414Source | 4,546,316Source | 3,308,360Source | 53,338,554Source | 8,749,925Source | 188,966,002Source | 81,639,296Source | 38,556,891Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 383,549Source | 322,447Source |
| Other General and Administrative ExpenseUSD | — | — | 1,421,255Source | 4,224,590Source | 1,766,210Source | 4,353,123Source | 2,410,516Source | — | 7,799,970Source | 17,880,050Source | 24,557,608Source | — |
| Research and Development ExpenseUSD | — | — | 15,946Source | — | 45,872Source | 161,084Source | 24,407Source | 390,189Source | 24,518Source | 537,428Source | 2,708,829Source | 4,165,197Source |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Gross Profit | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Interest and Other Income | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-282898
Filing attachments
e8019_ex99-1.htm · 8-K · 2026-10-23
Exhibit 99.1 Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister SACRAMENTO, Calif., October 22, 2026 - Lunai Bioworks Inc. (Nasdaq: LNAI) (the “Company”) announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2,500,000. The …
Read attachment ↗e7993_ex4-6.htm · 10-K · 2026-10-13
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of June 30, 2026, Lunai Bioworks, Inc. (the “Company,” “we,” “us” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.0001 per share (the “Common Stock”). The following summary describes the Common Stock and the provisions of our preferred stock …
Read attachment ↗e7731_ex99-1.htm · 8-K · 2026-06-17
EX-99.1 2 e7731_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS SACRAMENTO, Calif., June 17, 2026 Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology. I would like to update you on developments that have substantially strengthened our position and created mul…
Read attachment ↗e7662_ex99-1.htm · 8-K · 2026-05-20
EX-99.1 2 e7662_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT SACRAMENTO, California - May 20, 2026 - Lunai Bioworks, Inc. (Nasdaq: LNAI) (the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-8 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective at 12:01 a.m. Ea…
Read attachment ↗e7584_ex99-1.htm · 8-K · 2026-04-28
EX-99.1 2 e7584_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Lunai Bioworks, Inc. Announces Postponement of Special Meeting of Stockholders to May 8, 2026 SACRAMENTO, California - April 28, 2026 - Lunai Bioworks, Inc. (Nasdaq: LNAI) (the “Company”) today announced that it has postponed its Special Meeting of Stockholders (the “Special Meeting”), originally scheduled for May 4, 2026, to May 8, 2026 at 9:00 a.m. Eastern Time. The Special Meeting will continue to be held in a …
Read attachment ↗e7507_ex4-1.htm · 8-K · 2026-03-30
EX-4.1 2 e7507_ex4-1.htm EXHIBIT 4.1 EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT Lunai Bioworks inc. Warrant Shares: ________ Issue Date: ________ THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received ________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after the Issue Date (the “Initial Exercise Date”) and on or prior to the close of business on the Termi…
Read attachment ↗